Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Gallium Ga 68 OPS202

Known as: 68Ga-OPS202 
A radioconjugate consisting of the somatostatin antagonistic peptide OPS202 that is labeled with the positron-emitting radionuclide gallium Ga 68… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Somatostatin Receptor Antagonists for Imaging and Therapy.
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An… Expand
Is this relevant?
2017
2017
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.
Preclinical and preliminary clinical evidence indicates that radiolabeled somatostatin (sst) receptor antagonists perform better… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2017
2017
Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
Radiolabeled somatostatin (sst) receptor agonists are integral to the diagnosis of gastroenteropancreatic neuroendocrine tumors… Expand
Is this relevant?
2017
2017
Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201.
4094Background: Radiolabeled somatostatin receptor 2 (sstr2) antagonists have shown higher tumor uptake and tumor-to-organ ratios… Expand
Is this relevant?
2017
2017
Comparison of 68Ga-OPS202 (68Ga-NODAGA-JR11) and 68Ga-DOTATOC (68Ga-Edotreotide) PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Evaluation of Sensitivity in a Prospective Phase…
 
Is this relevant?
2016
2016
PET/CT with the somatostatin receptor antagonist 68Ga-OPS202 is twice as accurate as with the agonist 68Ga-DOTATOC for detecting liver metastases: Results of a phase 1/2 study in…
 
Is this relevant?
2015
2015
First clinical data on 68Ga-labeled somatostatin receptor antagonists: a phase I/II study comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT.
 
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE